Psychedelic Stocks

2020-10-21 PSW Editor

Mind Cure has acquired Epiphany360, a digital therapeutics platform for the treatment of mental health conditions.

2020-10-21 Jeff Nielson

With its new digital therapeutics platform, Mind Cure is positioning itself as an emerging leader in the psychedelic drug industry.

2020-10-21 PSW Editor

The latest psychedelic drug company to commence public trading is Psyched Wellness.

2020-10-19 PSW Editor

Cybin Corp. announces it has closed on an oversubscribed private placement of CAD$45 million as it prepares to go public.

2020-10-19 Jeff Nielson

The Compass Pathways IPO was a huge catalyst for the whole sector. Will a MindMed up-listing have the same impact?

2020-10-16 PSW Editor

Mydecine begins the dual listing process to obtain an LSE listing.

2020-10-16 Jeff Nielson

What is medtech? It's the wave of the future for healthcare.

2020-10-15 Jeff Nielson

Acute need. Huge markets. A wide-open playing field. Those are some of the best reasons to invest in psychedelic drug stocks.

2020-10-15 PSW Editor

Mind Cure brings in an expert in fintech to be its new CTO.

2020-10-14 Jeff Nielson

Both Numinus and Mydecine have been rising recently on big volume. Which is the better bet?

2020-10-14 PSW Editor

Numinus rolls out the list of Advisors on its psychedelics Advisory Council

2020-10-14 PSW Editor

Primo Nutraceuticals is commencing preliminary psychedelics research in a partnership with Mecan Biotech.